Proteins and nucleic acids useful in vaccines targeting
Disclosed are novel immunogenic proteins derived from Staphylococcus aureus , as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
1. A pharmaceutical composition comprising a polypeptide consisting of
a) an amino acid sequence consisting of amino acid residues 28-820 of SEQ ID NO: 13, or
b) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a) and having the same length as the amino acid sequence of a), or
c) an amino acid sequence consisting of at least 35 contiguous amino acid residues of 28-820 of SEQ ID NO: 13, or
d) an amino acid sequence of a), b) or c), which is fused or conjugated to an immunogenic carrier molecule or a tag, said pharmaceutical composition further comprising an immunological adjuvant and a pharmaceutically acceptable carrier, vehicle or diluent, and said polypeptide being antigenic in a mammal.
2. The pharmaceutical composition according to claim 1 , wherein the polypeptide is capable of inducing, in the mammal, an immune response against multi-resistant S. aureus infection.
3. The pharmaceutical composition according to claim 1 , wherein the immunological adjuvant is selected from an aluminum salt, an oil-in-water emulsion formulation, a saponin adjuvant, a cytokine, Complete Freund's Adjuvant (CFA), and Incomplete Freund's Adjuvant (IFA).
4. The pharmaceutical composition according to claim 3 , wherein the aluminum salt is aluminum hydroxide, aluminum phosphate, or aluminum sulfate.
5. The pharmaceutical composition according to claim 3 , wherein the oil-in-water emulsion is MF59, SAF, or a Ribi adjuvant system.
6. The pharmaceutical composition according to claim 3 , wherein the cytokine is selected from the group consisting of an interleukin, an interferon, M-CSF, and TNF.
7. A unit dose of a pharmaceutical composition comprising a polypeptide consisting of:
a) an amino acid sequence consisting of amino acid residues 28-820 of SEQ ID NO: 13, or
b) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a) and haying the same length as the amino acid sequence of a), or
c) an amino acid sequence consisting of at least 35 contiguous amino acid residues of 28-820 SEQ ID NO: 13, or
d) an amino acid sequence of a), b) or c), which is fused or conjugated to an immunogenic carrier molecule or a tag wherein the amount of said polypeptide is between 0.5 μg and 500 mg, said pharmaceutical composition further comprising a pharmaceutically acceptable carrier, vehicle or diluent, and said polypeptide being antigenic in a mammal.
8. The unit dose according to claim 7 , wherein the amount of said polypeptide does not exceed 5,000 μg.
9. The unit dose according to claim 8 , wherein the amount of said polypeptide is in the range between 10 and 200 μg.
10. The unit dose according to claim 7 , further comprising an immunological adjuvant.
11. The unit dose according to claim 10 , wherein the immunological adjuvant is selected from an aluminium salt, an oil-in-water emulsion formulation, a saponin adjuvant, a cytokine, Complete Freund's Adjuvant (CFA), and Incomplete Freund's Adjuvant (IFA).
12. The unit dose according to claim 11 , wherein the aluminium salt is aluminium hydroxide, aluminium phosphate, or aluminium sulfate.
13. The unit dose according to claim 11 , wherein the oil-in-water emulsion is MF59, SAF, or a Ribi adjuvant system.
14. The unit dose according to claim 11 , wherein the cytokine is selected from the group consisting of an interleukin, an interferon, M-CSF, and TNF.